Compare · DXCM vs MODD
DXCM vs MODD
Side-by-side comparison of DexCom Inc. (DXCM) and Modular Medical Inc. (MODD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and MODD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.10B, about 1613.7x MODD ($20.5M).
- MODD has been more active in the news (11 items in the past 4 weeks vs 6 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 0 for MODD).
- Company
- DexCom Inc.
- Modular Medical Inc.
- Price
- -
- -
- Market cap
- $33.10B
- $20.5M
- 1M return
- -
- -4.60%
- 1Y return
- -
- -86.79%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 6
- 11
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Modular Medical Inc.
Modular Medical, Inc., a development stage medical device company, focuses on the design, development, and commercialization of insulin pumps using technology to enhance pump adoption in the diabetes marketplace. The company is headquartered in San Diego, California.
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Latest MODD
- Modular Medical Launches Digital Learning Tools to Support Adoption of Pivot Insulin Delivery System
- Modular Medical to Present at the Webull Emerging & Innovative Companies Webinar on October 14th
- Director Felsher Steven G was granted 25 shares, increasing direct ownership by 0.29% to 8,538 units (SEC Form 4)
- Director Desisto Duane M was granted 83 shares, increasing direct ownership by 0.89% to 9,412 units (SEC Form 4)
- Director Volkart Carmen B was granted 108 shares, increasing direct ownership by 12% to 1,036 units (SEC Form 4)
- SEC Form 4 filed by Director Goldberg Jeff D
- SEC Form 4 filed by Director Vos Ellen O'Connor
- SEC Form 4 filed by Director Sheibley Philip Brent
- SEC Form 4 filed by Director Frank Morgan C.
- SEC Form DEF 14A filed by Modular Medical Inc.